Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers… Read more
Plus Therapeutics Inc (PSTV) - Total Assets
Latest total assets as of September 2025: $18.67 Million USD
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) holds total assets worth $18.67 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Plus Therapeutics Inc - Total Assets Trend (1998–2024)
This chart illustrates how Plus Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Plus Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Plus Therapeutics Inc's total assets of $18.67 Million consist of 79.3% current assets and 20.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.2% |
| Accounts Receivable | $571.00K | 8.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $469.00K | 7.1% |
| Goodwill | $372.00K | 5.6% |
Asset Composition Trend (1998–2024)
This chart illustrates how Plus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Plus Therapeutics Inc's current assets represent 79.3% of total assets in 2024, an increase from 3.4% in 1998.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 3.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Plus Therapeutics Inc Competitors by Total Assets
Key competitors of Plus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Plus Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Plus Therapeutics Inc generates 0.88x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Plus Therapeutics Inc is currently not profitable relative to its asset base.
Plus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 0.44 | 1.07 |
| Quick Ratio | 1.29 | 0.44 | 1.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.97 Million | $ -6.75 Million | $ 636.00K |
Plus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Plus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.19 |
| Latest Market Cap to Assets Ratio | 4.53 |
| Asset Growth Rate (YoY) | -41.8% |
| Total Assets | $6.63 Million |
| Market Capitalization | $30.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Plus Therapeutics Inc's assets at a significant premium ( 4.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Plus Therapeutics Inc's assets decreased by 41.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Plus Therapeutics Inc (1998–2024)
The table below shows the annual total assets of Plus Therapeutics Inc from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.63 Million | -41.75% |
| 2023-12-31 | $11.39 Million | -52.29% |
| 2022-12-31 | $23.87 Million | +8.58% |
| 2021-12-31 | $21.98 Million | +81.59% |
| 2020-12-31 | $12.11 Million | -47.89% |
| 2019-12-31 | $23.23 Million | -3.18% |
| 2018-12-31 | $23.99 Million | -24.12% |
| 2017-12-31 | $31.61 Million | -8.65% |
| 2016-12-31 | $34.61 Million | -8.19% |
| 2015-12-31 | $37.70 Million | -2.64% |
| 2014-12-31 | $38.72 Million | -7.94% |
| 2013-12-31 | $42.06 Million | -2.75% |
| 2012-12-31 | $43.25 Million | -16.07% |
| 2011-12-31 | $51.53 Million | -22.33% |
| 2010-12-31 | $66.35 Million | +168.08% |
| 2009-12-31 | $24.75 Million | -3.36% |
| 2008-12-31 | $25.61 Million | +19.07% |
| 2007-12-31 | $21.51 Million | -13.52% |
| 2006-12-31 | $24.87 Million | -11.71% |
| 2005-12-31 | $28.17 Million | +10.59% |
| 2004-12-31 | $25.47 Million | -9.32% |
| 2003-12-31 | $28.09 Million | -28.56% |
| 2002-12-31 | $39.32 Million | -8.86% |
| 2001-12-31 | $43.14 Million | -17.46% |
| 2000-12-31 | $52.27 Million | +837.56% |
| 1999-12-31 | $5.58 Million | +446.57% |
| 1998-12-31 | $1.02 Million | -- |